We all know that T cell activation need both TCR and co-stimulatory signals, but how does CD3-targeted T-cell redirecting antibody, like Blinatumomab, directly activate T cells? Especially for solid tumors, how can anti-CD3 alone activate T cells? Thanks.
Dear Yang Xu,
You could look here:
https://en.wikipedia.org/wiki/Blinatumomab
Best regards,
Thomas
Dear Yang,
Im my opinion, a picture is worth a thousand words!
But here are some words to you:
Blinatumomab is a bispecific CD19-directed CD3 T cell engager (BiTE®) antibody construct that binds specifically to CD19 expressed on the surface of cells of B-lineage origin and CD3 expressed on the surface of T cells. BiTE® antibody constructs are a type of immunotherapy being investigated for fighting cancer by helping the body's immune system to detect and target malignant cells. The modified antibodies are designed to engage two different targets simultaneously, thereby juxtaposing T cells (a type of white blood cell capable of killing other cells perceived as threats) to cancer cells. BiTE® antibody constructs help place the T cells within reach of the targeted cell, with the intent of allowing T cells to inject toxins and trigger the cancer cell to die (apoptosis).
(from: http://investors.amgen.com/phoenix.zhtml?c=61656&p=RssLanding&cat=news&id=2116999 )
Best regards,
Thomas
P.S.:
In 2015, I visited China and Chengdu, too.
I attend to the Chengdu Research Base of Giant Panda Breeding ( 成都大熊貓繁育研究基地 / 成都大熊猫繁育研究基地 ).
Best regards,
Thomas
Dear Thomas,
The info you provided is of great help to me, I really appreciate it.
P.S.: I am not an aborigine, but I have been living in Chengdu for more than 8 years and I am obsessed with everything here. Just like an idiom in China, Chengdu is a city where you never want to leave once you come. You are warmly welcome to visit Chengdu again.
BRs,
Yang
- Badges
- Science topic
- Similar topics
- Biological Science
- Immunology
- Antibodies